Sarepta Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA. 

CEO
Michael E. Severino
CEOMichael E. Severino
Employees
835
Employees835
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1980
Founded1980
Employees
835
Employees835

SRPT Key Statistics

Market cap
1.89B
Market cap1.89B
Price-Earnings ratio
-5.79
Price-Earnings ratio-5.79
Dividend yield
Dividend yield
Average volume
3.48M
Average volume3.48M
High today
$16.98
High today$16.98
Low today
$16.38
Low today$16.38
Open price
$16.50
Open price$16.50
Volume
1.27M
Volume1.27M
52 Week high
$25.32
52 Week high$25.32
52 Week low
$14.68
52 Week low$14.68

Stock Snapshot

With a market cap of 1.89B, Sarepta Therapeutics(SRPT) trades at $16.94. The stock has a price-to-earnings ratio of -5.79.

During the trading session on 2026-08-10, Sarepta Therapeutics(SRPT) shares reached a daily high of $16.98 and a low of $16.38. At a current price of $16.94, the stock is +3.4% higher than the low and still -0.2% under the high.

Trading volume for Sarepta Therapeutics(SRPT) stock has reached 1.27M, versus its average volume of 3.48M.

Over the past 52 weeks, Sarepta Therapeutics(SRPT) stock has traded between a high of $25.32 and a low of $14.68.

Over the past 52 weeks, Sarepta Therapeutics(SRPT) stock has traded between a high of $25.32 and a low of $14.68.

SRPT News

Simply Wall St 14h
Why Sarepta Therapeutics Is Up 12.9% After Cutting 2026 Guidance And Naming A New CEO

Sarepta Therapeutics recently narrowed its 2026 total net product revenue guidance to US$1.20 billion–US$1.30 billion and reported second-quarter 2026 revenue o...

Why Sarepta Therapeutics Is Up 12.9% After Cutting 2026 Guidance And Naming A New CEO
Simply Wall St 2d
Sarepta Therapeutics Brings In Michael Severino As Chief Executive Officer

Sarepta Therapeutics (NasdaqGS:SRPT) appointed Michael Severino, M.D., as Chief Executive Officer and member of the Board of Directors. Severino joins Sarepta...

Sarepta Therapeutics Brings In Michael Severino As Chief Executive Officer
TipRanks 4d
Sarepta Therapeutics Balances Profit Gains With Revenue Strain

Sarepta Therapeutics Inc. ((SRPT)) has held its Q2 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock powerful investing...

Analyst ratings

46%

of 26 ratings
Buy
30.8%
Hold
46.2%
Sell
23.1%

More SRPT News

TipRanks 4d
Analyst Reiterates Sell on Sarepta as Core Franchise Weakens and Pipeline Remains Uncertain; $5 Price Target Unchanged

H.C. Wainwright analyst Mitchell Kapoor reiterated a Sell rating on Sarepta Therapeutics today and set a price target of $5.00. Unlock powerful investing tools...

TipRanks 4d
Gil Blum Reiterates Sell on Sarepta as 2026 Guidance Trimmed and Regulatory Uncertainty Weighs on Growth Outlook

Needham analyst Gil Blum has reiterated their bearish stance on SRPT stock, giving a Sell rating today. Unlock powerful investing tools with TipRanks Premium t...

People also own

Based on the portfolios of people who own SRPT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.